Edward Hu has been appointed co-chief executive officer of WuXi AppTec. Mr. Hu will continue to report to Dr. Ge Li, Chairman and chief executive officer of WuXi AppTec.

Mr. Hu will share business management responsibilities with Dr. Li, including the small molecule drug discovery, development, manufacturing services, drug and medical device testing services. Mr. Hu will continue to act as the chief financial officer in charge of corporate finance, investment, and mergers and acquisitions, until a new CFO is named.

Since joining WuXi in 2007, Mr. Hu has served as the company’s chief operating officer, and later chief financial officer and chief investment officer. Over the past decade, he has made significant achievements in operational excellence, financial management, and WuXi’s global business expansion. Mr. Hu was elected to the Board of Directors in March 2016.
Prior to WuXi, Mr. Hu served as senior vice president and chief operating officer at Tanox.

“Ed’s extraordinary business leadership has been, and will continue to be critical to the growth of WuXi AppTec,” said Dr. Ge Li, chairman and chief executive officer of WuXi AppTec. “I look forward to working closely with Ed as we enter an exciting new era of growth, and please join me in wishing him even greater success in his new role.”

“I’m very grateful for the trust placed in me by the board and Dr. Li,” said Mr. Hu. “It’s our vision to enable anyone and any company to realize their R&D dream, so that patients can benefit from earlier access to better medicines. Together, we will strive to fulfill WuXi’s dream that every drug can be made and every disease can be treated.”